qbet casino
KNOXVILLE, Tenn. (AP) — Chaz Lanier scored 18 and No. 7 Tennessee extended its season-opening winning streak to seven games with a 78-35 victory over UT Martin on Wednesday. Felix Okpara had 10 points and 11 rebounds for the Volunteers (7-0). Zakai Zeigler added 11 points and nine assists, and Igor Milicic had 13 rebounds and nine points. The Skyhawks (2-5) were led by Josu Grullon's 15 points. Lanier scored 11 points in the first half as Tennessee built a 35-20 lead at the half. Grullon had 10 for UT Martin. UT Martin: Dropped its fifth straight after two opening wins under first-year coach Jeremy Shulman. After 21 wins last year, the Skyhawks brought in 16 newcomers this season. They are picked to finish 10th in the Ohio Valley Conference. Tennessee: After receiving the news that 6-foot-9 sophomore J.P. Estrella will miss the entire season with a foot injury, the Vols have had to go back to the drawing board to determine their rotation on the front court. Estrella had been coming off the bench with Cade Phillips to spell Igor Milicic and Felix Okpara. What that big man rotation looks like will be interesting. From late in the first half to early in the second half, Tennessee scored 14 straight points and turned a 10-point lead into a 44-20 advantage. Zakai Zeigler had five of those points. UT Martin committed 18 turnovers. Five of those were shot-clock violations. Tennessee scored 24 points off the turnovers. UT Martin will be at Charleston Southern next Tuesday. Tennessee will host Syracuse next Tuesday in the SEC/ACC Challenge. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketballUS-Google face off as ad tech antitrust trial comes to close
KyKy Tandy scored a season-high 21 points that included a key 3-pointer in a late second-half surge as Florida Atlantic roared back to beat Oklahoma State 86-78 on Thursday in the opening round of the Charleston Classic in Charleston, S.C. Florida Atlantic (4-2) advances to play Drake in the semifinal round on Friday while the Cowboys square off against Miami in the consolation semifinal contest, also Friday. Oklahoma State led by as many as 10 points in the first half before securing a five-point advantage at halftime. The Owls surged back and moved in front with four and a half minutes to play. It was part of an 11-1 run, capped by a 3-pointer from Tandy that made it 75-68 with 2:41 remaining. Ken Evans added 14 points for Florida Atlantic, with Leland Walker hitting for 13 and Tre Carroll scoring 11. The Owls went 35-of-49 from the free throw line as the teams combined for 56 fouls in the game, 33 by Oklahoma State. Khalil Brantley led Oklahoma State (3-1) with 16 points while Robert Jennings added 14 points and 11 rebounds for the Cowboys, who hit one field goal over a 10-minute stretch of the second half while having three players foul out. The Owls were up by as many as seven points in the early minutes and by 13-10 after a layup by Carroll at the 11:32 mark of the first half. Oklahoma State leapfrogged to the front on Abou Ousmane's layup off a Brantley steal, fell behind again on a 3-pointer by Evans and then responded on a 3-pointer by Jennings to take a 17-16 lead. From there, the Cowboys stoked their advantage to double digits when Jamyron Keller canned a shot from beyond the arc with five minutes to play in the half. Florida Atlantic got a layup and a monster dunk from Matas Vokietaitis and a pair of free throws from Walker in a 6-2 run to end the half to pull within 39-34 at the break. Jennings and Ousmane tallied seven points apiece for Oklahoma State over the first 20 minutes, as the Cowboys led despite shooting just 33.3 percent from the floor in the half. Carroll and Vokietaitis scored seven points apiece to pace the Owls, who committed 11 turnovers that translated to seven points for Oklahoma State before halftime. --Field Level Media
Parsons to Present at Investor ConferencesInnovative immunotherapy shows promise in early clinical trial for breast cancer December 5, 2024 Kent State University A groundbreaking phase one clinical trial explored a novel cell-based immunotherapy for breast cancer. The study focuses on a new treatment approach that aims to harness the body's immune system to enhance patient responses and reduce the need for conventional chemotherapy and its associated toxicities. The trial involved 12 patients with locally advanced stage I-III HER2 breast cancer. Facebook Twitter Pinterest LinkedIN Email A groundbreaking phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer has been accepted for publication in JAMA Oncology. The technology tested in the trial was co-developed by Gary Koski, Ph.D., professor in Kent State University's Department of Biological Sciences, and Brian J. Czerniecki, M.D., Ph.D., chair and senior member in the Moffitt Cancer Center's Department of Breast Oncology. The study focuses on a new treatment approach that aims to harness the body's immune system to enhance patient responses and reduce the need for conventional chemotherapy and its associated toxicities. The trial involved 12 patients with locally advanced stage I-III HER2 breast cancer. This research builds upon insights gained from previous studies funded by a Department of Defense Breakthrough Award research grant. "We are hopeful that we will be able to use this new immunotherapy instead of chemotherapy, or at least dramatically reduce the need for chemotherapy, for all types of breast cancer," Czerniecki said. The immunotherapy leverages dendritic cells, critical components of the immune system that normally identify infection and mobilize other elements of immunity to repel a microbial attack. By removing some of these dendritic cells from the body, biochemically reprogramming them for anti-cancer activity and injecting them directly into breast tumors, the researchers could trigger a powerful, organized immune system attack on the cancer. This led to the significant shrinkage of tumors before standard chemotherapy was administered. Eight out of the 12 patients demonstrated at least a 50% reduction in tumor volume after just six weeks of immunotherapy. This treatment produced only minimal side effects, primarily mild flu-like symptoms, compared with the severe side effects often associated with traditional chemotherapy. "These exciting results are the culmination of nearly 30 years of collaborative research between my laboratory and Dr. Czerniecki's," Koski said. The researchers have already begun a larger phase two trial to test higher doses of the immunotherapy, further exploring the potential effectiveness of this new technology. The published clinical trial was supported by the Moffitt Breast Cancer Research Fund, the Don Shula Foundation and donations from the Pennies in Action organization, which has raised approximately $7 million over the last decade to support this innovative cancer research. This unique funding model allows patients to directly contribute to advancements in treatments that may benefit them and others in the future. Story Source: Materials provided by Kent State University . Original written by Jim Maxwell. Note: Content may be edited for style and length. Journal Reference : Cite This Page :